Gritstone’s Phase 2 cancer vaccine trial misses the mark, stock spirals down

Grit­stone bio’s stock took a tum­ble in pre­mar­ket trad­ing Tues­day morn­ing fol­low­ing mixed da­ta from a Phase 2 study of its can­cer vac­cine, but it’s still mov­ing ahead with a pub­lic of­fer­ing of its stock and Phase 3 plan­ning.

In a late Mon­day re­lease, Grit­stone tout­ed the da­ta as pos­i­tive from the Phase 2 por­tion of its Phase 2/3 GRAN­ITE tri­al of its neoanti­gen can­cer vac­cine in front-line metasta­t­ic mi­crosatel­lite sta­ble col­orec­tal can­cer (MSS-CRC). Pro­gres­sion-free sur­vival fa­vored Grit­stone’s vac­cine in an ear­ly trend, even though the dataset is “im­ma­ture,” the com­pa­ny said in its pre­sen­ta­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.